“The United States is a strategically important market for Calmino. Through Immuron, we gain an established partner with experience in the U.S. market and a clear focus on digestive health. For a smaller Swedish life science company, bringing a proprietary product from Gothenburg to the United States represents a major milestone,” says Tobias Kisker, CEO and Founder of Calmino group AB.
Calmino is based at Sahlgrenska Science Park in Gothenburg, where the company develops and commercializes science-based products for gastrointestinal health.
PROIBS® was launched in Swedish pharmacies in 2010 and is designed to relieve symptoms associated with IBS, including abdominal pain, bloating, diarrhea and constipation.
According to sales data from IQVIA, PROIBS® was the best-selling IBS product in Swedish pharmacies in 2025. The product is now entering the US market, where the market for gastrointestinal health supplements is estimated to be worth USD 4.16 billion.
Calmino already exports to 16 countries across Europe, the Middle East and Australia. The US agreement marks another step in the company's international expansion.
"Entering the US market has always been one of our key ambitions. The US agreement is therefore an important milestone for us. Our next step is Germany, where we plan to launch during the fourth quarter of 2026. Germany is also a strategically important market for Calmino", says Tobias Kisker.
Link to website: Calmino